Please use this identifier to cite or link to this item: http://scholarbank.nus.edu.sg/handle/10635/131993
Title: Treatment of chronic hepatitis B virus infection using a mutant recombinant human β-interferon. A preliminary study
Authors: Guan, R. 
Ng, H.S.
Yap, I. 
Leong, S.F.
Colby, C.B.
Wee, A. 
Ho, J.
Tan, L.H.
Smith, R.
Issue Date: 1991
Citation: Guan, R., Ng, H.S., Yap, I., Leong, S.F., Colby, C.B., Wee, A., Ho, J., Tan, L.H., Smith, R. (1991). Treatment of chronic hepatitis B virus infection using a mutant recombinant human β-interferon. A preliminary study. Drug Investigation 3 (2) : 82-91. ScholarBank@NUS Repository.
Abstract: 17 patients (14 men and 3 women) aged 21 to 49 with chronic hepatitis B infection were treated with a 28-day course of human recombinant β-interferon (with the cysteine residue at position 17 substituted by serine to enhance specific activity and stability) [rINF-B(ser)] to determine its efficacy, acceptability and tolerability. All patients with HBeAg-positive with detectable HBV-DNA in their sera for at least 3 months prior to therapy. Eight patients were randomly selected to receive 6 million U/day of this interferon for 28 days while 9 others received 30 million U/day for 28 days. Serum HBV-DNA levels dropped in all patients during treatment and were undetectable at the end of treatment in 3 of 9 (33%) patients receiving 30 million U/day. HBV-DNA reappeared in all 3 patients during follow-up but became undetectable again at 16 and 18 months after therapy. Serum HBV-DNA levels became undetectable in 2 other patients receiving 30 million U/day during followup and one of them became seronegative for HBeAg 10 months after treatment. Two of 8 patients receiving 6 million U/day had transient loss of serum HBV-DNA following treatment. No changes in liver histology were noted immediately after treatment. Adverse effects of therapy included fever, malaise and weight loss. Neutropenia necessitating dosage reduction was noted in 7 patients (5 of them were receiving 30 million U/day interferon). Human rINF-B(ser) is effective in reducing viral replication in chronic hepatitis B virus infection, but the optimal dose and duration of treatment for permanent elimination of viral replication is yet to be determined.
Source Title: Drug Investigation
URI: http://scholarbank.nus.edu.sg/handle/10635/131993
ISSN: 01142402
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

Page view(s)

17
checked on Oct 18, 2018

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.